SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ImmunityBio converts from Immunomedics
IBRX 2.110-1.4%Nov 6 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: CCS648 who wrote (1005)5/6/2025 2:03:33 PM
From: Maturin2 Recommendations

Recommended By
bobbseytwins2001
CCS648

   of 1229
 
The press release reads to me like a CYA from management/PSS to the new investors who placed money at $3 per share, and were likely viewing the papillary disease application as a near term catalyst that would further de-risk their investment. Regardless, count me as another person lowering their cost basis by purchasing shares yesterday and today. I still believe the product has value and with a market cap of under $2bn I like the risk/reward here.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News